BioAge appoints Dov Goldstein as Chief Financial Officer and Ann Neale as Chief Development Officer

RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge, a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO). Both officers are the first to hold their respective positions at BioAge.

“We are thrilled to welcome two seasoned industry leaders into the BioAge management team,” said Kristen Fortney, Ph.D., CEO of BioAge. “Dov has helped to build and finance multiple world-leading private and public companies, and brings valuable experience from previous roles in venture capital and operations in the biopharma industry, while Ann has deep experience managing large portfolios of clinical assets and scaling development programs. Following their decades of success in the biopharma sector, these two executives bring a perfect combination of energy and perspective that complements the company’s existing leadership as we grow the company and expand our portfolio of clinical programs that address diseases of aging.”

Goldstein comes to BioAge with extensive strategic financial experience in the biopharmaceutical sector. He joins BioAge from Indapta Therapeutics, where he served as chief financial and business officer from 2020 to 2021 and was responsible for the company’s growth strategies as well as operational finance and business development. Previously, he was CEO at RIGImmune from 2018 to 2020, CFO of Schrödinger from 2017 to 2018, and a partner at Aisling Capital from 2006 to 2017. From 2014 to 2015, he served as the CFO of Loxo Oncology, which was later acquired by Lilly for $8 billion. From 2000 to 2005, he served as CFO of Vicuron Pharmaceuticals (acquired by Pfizer in 2005 for $1.9 billion), where he raised over $250 million in equity financing and played major roles in the company’s partnership transactions. He currently serves on the board of directors of Gain Therapeutics, Neubase Therapeutics, and Coya Therapeutics, and previously held seats on the boards of ADMA Biologics, Cempra Pharmaceuticals, Durata Therapeutics, Esperion Therapeutics, and Loxo Oncology. He has an MD from Yale School of Medicine, an MBA from Columbia Business School, and a BS in Biological Sciences from Stanford University.

“The aging space is an unexplored frontier in biotech, with substantial challenges but even greater rewards,” said Goldstein. “The value of focusing on healthspan is very clear to me, from a market standpoint but also from a personal perspective, as I like so many others have seen the ravages of age-related disease in my own family. What makes BioAge so compelling is the creative and pragmatic way that the company uses its computational methods to identify aging drugs, identify practical indications, and move rapidly into the clinic. I’m eager to help BioAge secure the financial resources to support its important mission, as well as to join the company’s leadership team.”

Neale has over 25 years leadership experience as a biotech executive, leading global multidisciplinary teams to advance molecules through the development pipeline and deliver on strategic objectives. Most recently, she served as Senior Vice President (SVP) Development Operations at Principia Biopharma, where she defined operations and resourcing strategy for multiple global early and late phase clinical programs while scaling development functions. After Principia was acquired by Sanofi for $3.6 billion in September 2020, Neale led the transition and integration of global clinical development operations. Previously, she served as SVP Clinical Operations and Patient Affairs at Science 37 in 2017, VP Clinical Operations and Data Assessment at XOMA from 2014 to 2017, VP Clinical Operations at Biotie Therapies (acquired by Acorda Therapeutics) from 2007 to 2014, and VP Clinical Operations at Saegis Pharmaceuticals (acquired by Lundbeck) from 2004 to 2006. She holds a BS in Nursing from the University of Minnesota.

“I am impressed with the creative and practical foundation that BioAge has built in such a short time, as well as the company’s unique approach using the analytics platform to identify drug targets that impact aging. The potential to benefit patients and our society by uncovering new treatments that target the unmet needs of an aging population is so exciting. As Chief Development Officer, I’m eager to drive the strategies that are required to bring even more molecules from our data-driven platform into clinical development.”

About BioAge

BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging, thus revealing the causes of age-related disease. By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent these diseases in entirely new ways. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. BioAge currently has three clinical-stage programs in their growing portfolio. For additional information about BioAge, visit the company’s website at https://www.bioagelabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005482/en/